Bellicum to Participate in Two Upcoming Virtual Investor Conferences
Bellicum Pharmaceuticals (NASDAQ:BLCM) announced participation in two virtual investor conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Bellicum Pharmaceuticals (NASDAQ:BLCM) announced participation in two virtual investor conferences. The first is the Wells Fargo 2020 Virtual Healthcare Conference on September 9, 2020, at 12:40 p.m. EDT, featuring an analyst moderated discussion. The second is the H.C. Wainwright 22nd Annual Global Investment Conference on September 15, 2020, at 2:30 p.m. EDT, which will include a presentation. Live webcasts and archived versions of the events will be accessible on the company’s website.
Details
News Market Reaction – BLCM
The recorded move for BLCM in the trading session of this news was -3.53%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
HOUSTON, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that management will participate in two upcoming virtual investor conferences.
Conference Details:
Wells Fargo 2020 Virtual Healthcare Conference
Date/Time: Wednesday, September 9, 2020 at 12:40 p.m. EDT
Format: Analyst Moderated Discussion
H.C. Wainwright 22nd Annual Global Investment Conference
Date/Time: Tuesday, September 15, 2020 at 2:30 p.m. EDT
Format: Presentation
A live webcast of the analyst moderated discussion session at Wells Fargo and the H.C. Wainwright presentation may be accessed from the Events & Presentation section of the Bellicum website. An archived version of each webcast will be available for replay immediately following the event.
About Bellicum Pharmaceuticals
Bellicum is a clinical stage biopharmaceutical company striving to deliver cures through controllable cell therapies. The company’s next-generation product candidates are differentiated by powerful cell signaling technologies designed to produce more effective CAR-T and CAR-NK cell therapies. Bellicum’s GoCAR-T® product candidates, BPX-601 and BPX-603, are designed to be more efficacious CAR-T cell products capable of overriding key immune inhibitory mechanisms. More information about Bellicum can be found at www.bellicum.com.
Source: Bellicum Pharmaceuticals
Investors:
Robert H. Uhl
Managing Director
Westwicke ICR
858-356-5932
Robert.uhl@westwicke.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.